David Spellman
2018
In 2018, David Spellman earned a total compensation of $1.8M as Chief Financial Officer at Mersana Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $94,720 |
|---|---|
| Option Awards | $1,383,150 |
| Salary | $298,609 |
| Total | $1,776,479 |
Spellman received $1.4M in option awards, accounting for 78% of the total pay in 2018.
Spellman also received $94.7K in non-equity incentive plan and $298.6K in salary.
Rankings
In 2018, David Spellman's compensation ranked 6,330th out of 14,244 executives tracked by ExecPay. In other words, Spellman earned more than 55.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,330 out of 14,244 | 56th |
Division Manufacturing | 2,424 out of 5,762 | 58th |
Major group Chemicals And Allied Products | 902 out of 2,125 | 58th |
Industry group Drugs | 757 out of 1,814 | 58th |
Industry Pharmaceutical Preparations | 587 out of 1,388 | 58th |
Source: SEC filing on April 23, 2019.
Spellman's colleagues
We found three more compensation records of executives who worked with David Spellman at Mersana Therapeutics in 2018.